The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

References

• World Health Organization. Assessment of fracture risk and its application to screening for post menopausal osteoporosis. Technical report series 843. Geneva: World Health Organization; 1994
   Google Scholar
• National Osteoporosis Society website: What is osteoporosis? Available from http://www.nos.org.uk [accessed 31st July 2005]
   Google Scholar
• Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int 1998;8:611–7
   PubMed Web of Science ®Google Scholar
• Burge RT, Worley D, Johansen A, et al. The cost of osteoporotic fractures in the UK: projections for 2000–2020. J Med Econ 2001;4:51–3
   Google Scholar
• Office for National Statistics. Population projections 1998-based 2000; Series PP2 no 22
   Google Scholar
• Bailey K, Ellis C, Majeed A. Trends in the treatment of osteoporosis and types of drug treatment prescribed in general practice in England and Wales, 1994–1998. Health Statistics Quarterly 2002;16: 5–13
   Google Scholar
• The National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Final appraisal determination (2004). Available from http://www.nice.org.uk [accessed 30 Nov 2005]
   Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis Int 2003;14:808–13
   PubMed Web of Science ®Google Scholar
• Segal E, Tamir A, Ish-Shalom, S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859–62
   Google Scholar
• Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001;15:S529 [abstract M406]
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446–57
   PubMed Web of Science ®Google Scholar
• Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO Population. Am J Manag Care 1998;4:1421–30
   PubMed Web of Science ®Google Scholar
• Inui TS, Carter WB, Pecoraro RE, et al. Variations in patient compliance with common long-term drugs. Med Care 1980;18:986–93
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458–62
   PubMed Web of Science ®Google Scholar
• Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424–9
   PubMedGoogle Scholar
• Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. J Am Med Assoc 2002;288:495–7
   Web of Science ®Google Scholar
• Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medication using computer-based pharmacy records. Med Care 1997;35:1164–70
   PubMed Web of Science ®Google Scholar
• Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43–9
   PubMedGoogle Scholar
• Recker R, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of non-compliance and non-persistence with daily-regimen bisphosphonates on longer term effectiveness outcomes in patients with osteoporosis. Poster M423 presented at: the 26th Annual Meeting of the American Society for Bone Mineral Research October 1–5, 2004, Seattle
   Google Scholar
• Tosteson ANA, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 2003;14:259–62
   Google Scholar
• International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don’t continue with treatment. A European report highlighting the gap between the beliefs of people with osteoporosis and the perceptions of their physicians. 2005
   Google Scholar
• Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges and strategies. Clin Ther 1997:2;346–66
   Google Scholar
• De Wilde S, Carey JM, Bremner SA. A comparison of the recording of 30 common childhood conditions in the Doctors’ Independent Network and General Practice Research Databases. Health Statistics Quarterly 2004;22: 21–30
   Google Scholar
• Jick H. Further validation of information recorded on a general practitioner based computerised data resource in the UK. Pharmacoepidemiol Drug Saf 1992;1:347–9
   Google Scholar
• Lawrence M, Coulter A, Jones L. A total audit of preventative procedures in 45 practices caring for 430 000 patients. Br Med J 1990;300: 1501–3
   Google Scholar
• Defiled S, Carey JM, Brenner SA, et al. Evolution of statin prescribing 1994–2001: a case of ageism but not of sexism. Heart 2003;89:417–21
   PubMed Web of Science ®Google Scholar
• Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:P–297
   Google Scholar
• Finigan J, Bainbridge PR, Eastell R. Adherence to osteoporosis therapies. Osteoporosis Int 2001;12:S48–9 [abstract P110)]
   Google Scholar
• Ettinger B, Pressman AR, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions and discontinuation. J Managed Care Pharm 1998:4;488–92
   Google Scholar
• Boccuzzi SJ, Folz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005;16\(Suppl 4): S35–36 [abstract P7.10]
   Google Scholar
• Ettinger MP, Gallagher R, Amonkar M. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Arthritis Rheum 2004;15(Suppl):S513 [abstract 1325]
   Google Scholar
• Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomised, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandonate versus once-weekly alendronate in a randomized, open label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005:21;1895–903
   PubMed Web of Science ®Google Scholar
• Thompson PW, Cooper C, Carr AJ. Factors influencing adherence to bisphosphonates for osteoporosis. Arthritis Rheum 2005;52(Suppl):S257–S258
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Brankin E, Mitchell C, Munro R; Lanarkshire Osteoporosis Service. Closing the osteoporosis management gap on primary care: a secondary prevention of fracture programme. Curr Med Res Opin 2005;21:475–82
   Google Scholar
• Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;10;348:383–6
   Google Scholar